Ricardo Romagosa, MD
Dermatology · Stuart, FLNPI 1720075401
Payments from drug & device makers
Across 100 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$744
- Novartis$273
- Barco, Inc.$249
- LEO Pharma Inc.$145
- Sanofi$142
- Amgen$123
- plus $390 from 15 others
What the payments were for
- Food & beverage$2,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $744 |
| Novartis | 16 | $273 |
| Barco, Inc. | 1 | $249 |
| LEO Pharma Inc. | 8 | $145 |
| Sanofi | 6 | $142 |
| Amgen | 7 | $123 |
| Lilly USA, LLC | 4 | $71 |
| Johnson & Johnson | 2 | $40 |
| Bristol Myers Squibb | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 2 | $23 |
| UCB, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $16 |
| Verrica Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Almirall LLC | 1 | $14 |
| Kerecis Limited | 1 | $9 |
| Sensus Healthcare, Inc. | 1 | $3 |
How this compares
$2,066 in reported general payments places this provider in the 40th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 13 | $265,072 |
| Dupixent PenDupilumab | 59 | $217,509 |
| Gentamicin Sulfate | 64 | $2,235 |
| Betamethasone Dipropionate | 67 | $2,232 |
| Fluorouracil | 34 | $1,701 |
| Tacrolimus | 14 | $1,531 |
| Clobetasol Propionate | 63 | $1,356 |
| Doxycycline Hyclate | 84 | $1,304 |
| Triamcinolone Acetonide | 102 | $1,295 |
| Metronidazole | 27 | $1,280 |
| Ketoconazole | 42 | $555 |
| ValacyclovirValacyclovir Hcl | 20 | $540 |
| Hydrocortisone | 68 | $365 |
| Nystatin | 23 | $337 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Stuart
- John MinniStuart$1.4M
- Michael SherlingLake Worth$78.9M
- Seth FormanTampa$28.2M
- Thomas TaylorTampa$13.6M
- Frank DonHallandale Beach$7.5M
- Francisco FloresMiramar$6.7M
- Hector Wiltz JrMiami$6.4M
- Javier Alonso-LlamazaresCoral Gables$5.6M
- Eduardo WeissHollywood$5.5M
- Francisco KerdelMiami$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.